Metagenomi Inc (Ticker: MGX US) is a United States-based biotechnology company focused on advancing the field of gene editing through its innovative metagenomics-powered discovery platform. The company is scheduled to launch its initial public offering on the NASDAQ exchange, with an anticipated trading date of February 9, 2024. Metagenomi aims to raise USD 106.25 million by offering 6.25 million shares, with an expected price range of USD 15.00 to 17.00 per share. The offering includes a greenshoe option of 937,500 additional shares, potentially increasing the total offering size. The IPO is managed by a syndicate led by JP Morgan Securities LLC, alongside BMO Capital Markets Corp, Cowen & Co, Jefferies LLC, and Wells Fargo Securities LLC.

Metagenomi specializes in developing potentially curative therapies using next-generation gene editing technology. The company's research focuses on a wide array of diseases, including metabolic disorders, hemophilia A, cardiovascular diseases, central nervous system diseases, and cystic fibrosis, with all projects currently in preclinical development stages. Additionally, Metagenomi's platform targets immuno-oncology for ex vivo applications.